<DOC>
	<DOCNO>NCT00234468</DOCNO>
	<brief_summary>The aim study determine Iressa prolong period time without disease worsening ( Time progression ) patient previously treat combined therapy surgery chemotherapy without radiotherapy chemotherapy radiotherapy</brief_summary>
	<brief_title>Iressa v Placebo Maintenance Therapy Locally Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically Confirmed Non Small Cell Lung Cancer . Locally advance disease previously treat combine therapy ( chemotherapy surgery without radiotherapy , chemotherapy radiotherapy ) . Chemotherapy regimens contain cisplatin carboplatin mandatory Response combine therapy No previous treatment ZD1839 EGFRtargeted therapy No progressive disease combine therapy locally advance NSCLC No presence metastatic disease No coexisting malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Any unresolved chronic toxicity previous anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Locally Advanced Non Small Cell Lung Cancer ( Stage IIIA IIIB )</keyword>
</DOC>